Related references
Note: Only part of the references are listed.Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands
Corne H. W. Klaassen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing
Susanne Perkhofer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds
Manuel Cuenca-Estrella et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints
Paul E. Verweij et al.
DRUG RESISTANCE UPDATES (2009)
Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network
John W. Baddley et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network
S. Arunmozhi Balajee et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus
Alessandro C. Pasqualotto
MEDICAL MYCOLOGY (2009)
Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure
Susan J. Howard et al.
EMERGING INFECTIOUS DISEASES (2009)
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species
Jesus Guinea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus
Juan Luis Rodriguez-Tudela et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Activity of BAL 4815 against filamentous fungi
C. Martin de la Escalera et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Antifungal Drug Resistance in Molds: Clinical and Microbiological Factors
Laura Alcazar-Fuoli et al.
CURRENT FUNGAL INFECTION REPORTS (2008)
New and emerging treatments for fungal infections
A. C. Pasqualotto et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Aspergillus flavus:: human pathogen, allergen and mycotoxin producer
M. T. Hedayati et al.
MICROBIOLOGY-SGM (2007)
Comparison of two highly discriminatory molecular fingerprinting assays for analysis of multiple Aspergillus fumigatus isolates from patients with invasive aspergillosis
Hanneke A. de Valk et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
David W. Denning et al.
JOURNAL OF INFECTION (2006)
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts
F. Sabatelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program
J Morgan et al.
MEDICAL MYCOLOGY (2005)
Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli
MS Lionakis et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan:: Surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003
PR Hsueh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
J Maertens et al.
CLINICAL INFECTIOUS DISEASES (2004)
In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp.
A Gomez-Lopez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
DJ Diekema et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991)
A Espinel-Ingroff
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi
A Espinel-Ingroff
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Share Paper
